A. Cell proliferation was evaluated by CyQUANT assay performed on HDMECs in EBM as a starving medium (S.M.), EGM as a complete medium (C.M.) or stimulated for 24 and 48 hours with the supernatants of untreated, IL-17A- or IL-17A/TNF-α-treated keratinocytes (KC), in the presence or not of IL-36RA, Bevacizumab or Sunitinib. Data are shown as the percentage of mean values of fluorescence intensity obtained from three independent experiments ± SD. *p≤0.05, ** p≤0.01 by Kruskal Wallis test. B. ICAM-1 expression was evaluated by flow cytometry analysis on HDMECs stimulated for 36 hours with supernatants (Sup) of untreated, IL-17A- or IL-17A/TNF-α-treated KC in the presence or not of IL-36RA, Bevacizumab or Sunitinib. Data are expressed as mean fluorescence intensity (MFI) and represent one out of three independent experiments. Graphs show the MFI mean values of three different experiments performed ± SD. *p≤0.05, **p≤0.01 by Kruskal Wallis test.